Study uses data to tailor lung cancer care with immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Be well enough for treatment (ECOG 0–2, meaning you’re not severely limited)
- Have non-small-cell lung cancer that is stage IIIB, IIIC, or stage IV
- Have already received immunotherapy, or be eligible to start immunotherapy as first treatment (depending on the study group)
- Be able to share required study information and complete quality-of-life questionnaires if asked
- For the prospective (frontline) group: have an extra signed consent form and at least one tissue sample block available for lab testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized combination of radiation and immunotherapy for people with locally advanced non-small cell lung cancer that has a high level of a protein called PD-L1. It aims to improve treatment by tailoring the therapy to each patient's tumor.
This trial tests whether using a blood test to guide treatment can improve outcomes for people with advanced non-small cell lung cancer who are starting immunotherapy for the first time. Participants will receive standard immunotherapy tailored to their individual risk profile.
This trial uses real-world data to study how to personalize treatment for advanced non-small cell lung cancer. It looks at medical records from 2011 to 2024 to find the best therapy approaches.
This study looks at lung tumor tissue and blood to understand why immune checkpoint drugs can stop working in non-small cell lung cancer. It may help researchers find better ways to predict and overcome drug resistance.
This study collects blood and tissue samples from people with non-small cell lung cancer (NSCLC) either before or after treatment. It aims to help researchers learn more about how tumors respond, especially in cancers with specific genetic changes or after certain pre-surgery therapies.
This study is looking at immune markers in people with advanced non-small cell lung cancer (NSCLC) that cannot be cured. It tests how well the immune system responds to treatment, and may help guide future care.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.